Searched for: subject:"Animals"
(1 - 18 of 18)
document
Zacharowski, K. (author), Zacharowski, P.A. (author), Friedl, P. (author), Mastan, P. (author), Koch, A. (author), Boehm, O. (author), Rother, R.P. (author), Reingruber, S. (author), Henning, R. (author), Emeis, J.J. (author), Petzelbauer, P. (author), TNO Kwaliteit van Leven (author)
Many compounds have been shown to prevent reperfusion injury in various animal models, although to date, translation into clinic has revealed several obstacles. Therefore, the National Heart, Lung, and Blood Institute convened a working group to discuss reasons for such failure. As a result, the concept of adequately powered, blinded, randomized...
article 2007
document
Trion, A. (author), de Maat, M.P.M. (author), Jukema, J.W. (author), van der Laarse, A. (author), Maas, M.C. (author), Offerman, E.H. (author), Havekes, L.M. (author), Szalai, A.J. (author), Princen, H.M.G. (author), Emeis, J.J. (author), TNO Kwaliteit van Leven (author)
Objective - C-reactive protein (CRP) has been associated with risk of cardiovascular disease. It is not clear whether CRP is causally involved in the development of atherosclerosis. Mouse CRP is not expressed at high levels under normal conditions and increases in concentration only several-fold during an acute phase response. Because the...
article 2005
document
Verschuren, L. (author), Kleemann, R. (author), Offerman, E.H. (author), Szalai, A.J. (author), Emeis, S.J. (author), Princen, H.M.G. (author), Kooistra, T. (author), TNO Kwaliteit van Leven (author)
Objective - To evaluate whether low-dose atorvastatin suppresses atherosclerotic lesion progression and inflammation in apolipoprotein E*3 (apoE*3)-Leiden mice beyond its cholesterol-lowering effect. Methods and Results - ApoE*3-Leiden mice were fed a high-cholesterol (HC) diet until mild atherosclerotic lesions had formed. Subsequently, HC diet...
article 2005
document
Delsing, D.J.M. (author), Jukema, J.W. (author), van de Wiel, M.A. (author), Emeis, J.J. (author), van der Laarse, A. (author), Havekes, L.M. (author), Princen, H.M.G. (author), Gaubius Instituut TNO (author)
This study was designed to investigate the potential antiatherosclerotic effects of the calcium antagonist amlodipine as compared with the HMG-CoA reductase inhibitor atorvastatin and the combination of both in ApoE*3-Leiden transgenic mice. Four groups of 15 ApoE*3-Leiden mice were put on a high-cholesterol diet. One group received 0.002% (wt...
article 2003
document
Kleemann, R. (author), Princen, H.M.G. (author), Emeis, J.J. (author), Jukema, J.W. (author), Fontijn, R.D. (author), Horrevoets, A.J.G. (author), Kooistra, T. (author), Havekes, L.M. (author)
Background - Statins can exert anti-inflammatory antiatherosclerotic effects through an anti-inflammatory action, independent of lowering cholesterol. We addressed the question whether the anti-inflammatory activities of statins can reduce atherosclerosis beyond the reduction achieved by cholesterol lowering per se. Methods and Results - Two...
article 2003
document
Sakharov, D.V. (author), Jie, A.F.H. (author), Bekkers, M.E.A. (author), Emeis, J.J. (author), Rijken, D.C. (author), Gaubius Instituut TNO (author)
We present the first steps in the elaboration of an approach of extracellular matrix-targeted local drug delivery (ECM-LDD), designed to provide a high concentration, ubiquitous distribution, and long-term retention of a drug within the vessel wall after local intravascular delivery. The approach is based on the concept of a bifunctional drug...
article 2001
document
Lansink, M. (author), Jong, M. (author), Bijsterbosch, M. (author), Bekkers, M. (author), Toet, K. (author), Havekes, L. (author), Emeis, J. (author), Kooistra, T. (author), Gaubius instituut TNO (author)
Several clinical studies have demonstrated an inverse relationship between circulating levels of estrogen and tissue-type plasminogen activator (t-PA). The present study was designed to test the hypothesis that estrogen lower plasma levels of t-PA by increasing its clearance from the bloodstream. 17α-Ethinyl estradiol (EE) treatment resulted in...
article 1999
document
Gijbels, M.J.J. (author), van der Cammen, M. (author), van der Laan, L.J.W. (author), Emeis, J.J. (author), Havekes, L.M. (author), Hofker, M.H. (author), Kraal, G. (author), Gaubius instituut TNO (author)
Apolipoprotein E3-Leiden (APOE3-Leiden) transgenic mice develop hyperlipidemia and are highly susceptible to diet-induced atherosclerosis. We have studied the progression and regression of atherosclerosis using immunohistochemistry. Female transgenic mice were fed a moderate fat diet to study atherosclerosis over a longer time period. Fatty...
article 1999
document
Emeis, J.J. (author), Eijnden van den - Schrauwen, Y. (author), van den Hoogen, C.M. (author), de Priester, W. (author), Westmuckett, A. (author), Lupu, F. (author), Gaubius Instituut TNO (author)
In previous studies we have shown that, after stimulation by a receptor ligand such as thrombin, tissue-type plasminogen activator (tPA) and von Willebrand factor (vW(f)) will be acutely released from human umbilical vein endothelial cells (HUVEC). However, the mechanisms involved in the secretion of these two proteins differ in some respects,...
article 1997
document
Noorman, F. (author), Barrett-Bergshoeff, M.M. (author), Bekkers, M. (author), Emeis, J.J. (author), Rijken, D.C. (author), Gaubius Instituut TNO (author)
Dextran is used during surgery as a prophylactic agent to prevent deep venous thrombosis. Recently it has been shown that dextran increases t-PA plasma concentrations in patients. As dextran is a potential ligand for the mannose receptor, we studied whether this glucose-polymer would be able to inhibit mannose receptor-mediated clearance of t-PA...
article 1997
document
Padro, T. (author), Quax, P.H.A. (author), van den Hoogen, C.M. (author), Roholl, P. (author), Verheijen, J.H. (author), Emeis, J.J. (author), Gaubius Instituut TNO (author)
Plasminogen activator (PA) and PA inhibitor (PAI) antigen, activity, and mRNA were analyzed in the three layers of rat aorta, and the effect of endotoxin on PA and PAI was studied. All PA activity in aorta was identified as tissue-type PA (TPA) activity; no urokinase-type PA was detected. In the tunica adventitia TPA activity, TPA antigen, and...
article 1994
document
Schrauwen, Y. (author), de Vries, R.E.M. (author), Kooistra, T. (author), Emeis, J.J. (author), TNO Preventie en Gezondheid (author)
The acute release of t-PA was studied in vitro in human endothelial cells from different origin. It proved possible to enhance the amounts of t-PA which can be released by increasing t-PA synthesis, both in vitro, and in vivo in rats. These data suggest the feasibility to induce and (or) enhance acute release of t-PA in man. Chemicals/CAS:...
article 1994
document
Padró, T. (author), van den Hoogen, C.M. (author), Emeis, J.J. (author), Instituut voor verouderings- en vaatziekten onderzoek TNO (author)
The aim of the present study was to investigate whether hypothyroidism would affect the components of the rat plasma fibrinolytic system. Hypothyroidism was induced by feeding rats a thiouracil-containing diet for 2 weeks. During this period, half of the animals received subcutaneous injections of L-thyroxine (20 μg/kg daily) to restore thyroid...
article 1993
document
Emeis, J.J. (author), Verheijen, J.H. (author), Instituut voor Verouderings- en Vaatziekten Onderzoek TNO (author)
Chemicals/CAS: Recombinant Proteins; Tissue Plasminogen Activator, EC 3.4.21.68
article 1992
document
Padró, T. (author), van den Hoogen, C.M. (author), Emeis, J.J. (author), Gaubius Instituut TNO (author)
Tissue-type plasminogen activator (PA) activity and antigen was measured in nine different tissues from healthy rats (brain, lung, heart, liver, spleen, kidney, adrenal, aorta and skeletal muscle). After extraction in a KSCN buffer (for kidney) or in an acid acetate buffer (for all other tissues), total PA activity was determined by an improved...
article 1990
document
Wasser, M.N.J.M. (author), Koppert, P.W. (author), Arndt, J.W. (author), Emeis, J.J. (author), Feitsma, R.I.J. (author), Pauwels, E.K.J. (author), Nieuwenhuizen, W. (author), Gaubius Instituut TNO (author)
Balb/c mice were immunized with human plasmin-generated fibrinogen degradation product Y. Spleen cells were fused with P3X63-Ag8.653 myeloma cells. A clone (Y22) was found that produces monoclonal antibodies (MoAbs) with a strong reactivity with human fibrin and only a weak reactivity with fibrinogen in an enzyme immunoassay (EIA). Y22 also...
article 1989
document
Emeis, J.J. (author), Kluft, C. (author), Gaubius instituut TNO (author)
Platelet-activating factor (PAF-acether; 1-O-octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine) induced the release of plasminogen activator in rat, both in vivo and in perfused hind legs. The released plasminogen activator was shown by immunologic and functional criteria to be tissue-type plasminogen activator (t-PA). Release of t-PA by PAF...
article 1985
document
van Pelt Verkuil, E. (author), Emeis, J.J. (author), Gaubius instituut TNO (author)
Immunohistochemically, coagulation F-VIII-R:AG in vascular endothelial cells can be demonstrated with antihuman F-VIII-R:AG antisera after fixation with 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide, using both peroxidase and fluorescence techniques. The generally used aldehyde containing fixatives, result in a loss of immunoreactivity....
article 1981
Searched for: subject:"Animals"
(1 - 18 of 18)